A Pilot Study to Evaluate Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

Trial ID: NCT06377371

Interventional - Phase 4 - Recruiting

The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.

Conditions

• Meningioma

Interventions

• Brain Imaging with [Cu64]DOTATATE
• Radio-guided Surgery With Neoprobe Utilization

Eligibility

Inclusion criteria

• High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery.

Exclusion criteria

• Pregnant or breastfeeding
• Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
• Patients with hypersensitivity to somatostatin analogs
• Patients with contraindications to conventional MRI
• Patients with prior history of cranial radiation therapy
• Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded

Sponsor

Weill Medical College of Cornell University, Curium US LLC

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows